Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn's disease patients

Medical Science Monitor

Volumn 19, Issue 1, 2013, Pages 716-722

  de Souza, Gláucio Silva ^a   Vidigal, Fernando Mendonça ^a   Chebli, Liliana Andrade ^a   da Rocha Ribeiro, Tarsila Campanha ^a   Vasconcellos Furtado, Maria Cristina ^a   de Lima Pace, Fábio Heleno ^a   de Miranda Chaves, Leonardo Duque ^a   de Oliveira Zanini, Karine Andrade ^a   Gaburri, Pedro Duarte ^a   de Azevedo Lucca, Fernando ^a   Zanini, Alexandre ^a   Ribeiro, Luiz Cláudio ^a   Chebli, Julio Maria Fonseca ^a  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

Azathioprine; Crohn's disease; Hospitalization; Inflammatory bowel disease; Mesalazine; Surgery

Indexed keywords

AZATHIOPRINE; HYDROCORTISONE; MESALAZINE; PREDNISONE;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; INTESTINE INFECTION; INTESTINE OBSTRUCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SUBOCCLUSIVE ILEOCECAL CROHN DISEASE; SURVIVAL;

ADULT; AZATHIOPRINE; CROHN DISEASE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MESALAMINE; MIDDLE AGED; PATIENT READMISSION;

EID: 84883716289     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.889196     Document Type: Article

References (23)

1. Pinto AL, Chebli LA, Ribeiro MS et al: Azathioprine therapy in steroid-dependent patients with Crohn disease: results of a 10-year longitudinal follow-up study. Med Sci Monit, 2009; 15(5): PI19-26
2. Freeman HJ: Long-term natural history of Crohn's disease. World J Gastroenterol, 2009; 15: 1315-18
3. Bernstein CN, Loftus EV Jr, Ng SC et al: Hospitalisations and surgery in Crohn's disease. Gut, 2012; 61: 622-29
4. Bassi A, Dodd S, Williamson P, Bodger K: Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut, 2004; 53: 1471-78
5. Bodger K: Cost of illness of Crohn's disease. PharmacoEconomics, 2002; 20: 639-52
6. Odes S, Vardi H, Friger M et al: Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology, 2006; 131: 719-28
7. Feagan BG, Vreeland MG, Larson LR, Bala MV: Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol, 2000; 95: 1955-60
8. Yu AP, Cabanilla LA, Wu EQ et al: The costs of Crohn's disease in the United States and other western countries: a systematic review. Curr Med Res Opin, 2007; 24: 319-28
9. Caprilli R, Andreoli A, Capurso L et al: Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther, 1994; 8: 35-43
10. Hanauer SB, Stromberg U: Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol, 2004; 2: 379-88
11. Candy S, Wright J, Gerber M et al: A controlled double blind study of azathioprine in the management of Crohn's disease. Gut, 1995; 37: 674-78
12. Yaffe BH, Korelitz BI: Prognosis for nonoperative management of small bowel obstruction in Crohn's disease. J Clin Gastroenterol, 1983; 5: 211-15
13. Yu AP, Cabanilla LA, Wu EQ et al: The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin, 2008; 24: 319-28
14. Odes S, Vardi H, Friger M et al: Cost analysis and cost determinants in a European Inflammatory Bowel Disease Inception cohort with 10 years of follow-up evaluation. Gastroenterology, 2006; 131: 719-28
15. Punati J, Markowitz J, Lerer T et al: Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis, 2008; 14: 949-54
16. Cohen RD, Larson LR, Roth JM et al: The cost of hospitalization in Crohn's disease. Am J Gastroenterol, 2000; 95: 524-30
17. Herrinton LJ, Liu L, Fireman B et al: Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology, 2009; 137: 502-11
18. Sandborn W, Sutherland L, Pearson D et al: Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev, 2000(2): CD000545. Epub 2000/05/05
19. Chebli JM, Gaburri PD, De Souza AF et al: Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study. J Gastroenterol Hepatol, 2007; 22: 268-74
20. Picco MF, Zubiaurre I, Adluni M et al: Immunomodulators are associated with a lower risk of first surgery among patients with non-penetratingnonstricturing Crohn's disease. Am J Gastroenterol, 2009; 104: 2754-59
21. Papay P, Reinisch W, Ho E et al: The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. Am J Gastroenterol, 2010; 105: 1158-64
22. D'Haens G, Geboes K, Rutgeerts P: Endoscopic and histologic healing of Crohn's(ileo-) colitis with azathioprine. Gastrointest Endosc, 1999; 50: 667-71
23. Lee Y, Fleming FJ, Deeb AP et al: A laparoscopic approach reduces short-term complications and length of stay following ileocolic resection in Crohn's disease: an analysis of outcomes from the NSQIP database. Colorectal Disease, 2012; 14: 572-77